38 patents
Page 2 of 2
Utility
Combination Compositions for Treatment of Cancer
6 May 21
Provided are methods for treating cancer in a patient by administering at least one antibiotic selected from the group consisting of clofazimine, rifabutin and clarithromycin, in combination with an aryladamantane compound.
Reza Fathi, Dror Ben-Asher, Danielle Abramson
Filed: 12 Jan 21
Utility
Method for treating cancer with combination therapy
16 Mar 21
Provided are methods for treating cancer in a patient by administering at least one antibiotic selected from the group consisting of clofazimine, rifabutin and clarithromycin, in combination with an aryladamantane compound.
Reza Fathi, Dror Ben-Asher, Danielle Abramson
Filed: 17 Sep 19
Utility
Methods for treating helicobacter pylori infection
26 Jan 21
Single oral solid dosage form comprising an immediate release first dosage composition having at least two antibiotic agents and a delayed release second dosage composition having a proton pump inhibitor are provided herein.
Reza Fathi, Gilead Raday, Guy Goldberg, Patrick Gosselin
Filed: 13 Feb 19
Utility
Bimodal Release Ondansetron Tablets and Methods of Treating Nausea and Vomiting
21 Oct 20
A solid oral dosage form includes a core comprising a non-ionic polymer matrix, a first amount of a first antiemetic drug or a pharmaceutically acceptable salt thereof dispersed within the matrix, and a salt dispersed within the matrix; a first seal coat of a non-ionic polymer matrix surrounding the core; and an immediate release drug layer surrounding the first seal coat, wherein the immediate release drug layer comprises a non-ionic polymer and a second amount of a second antiemetic drug or a pharmaceutically acceptable salt thereof dispersed therein, wherein the drug layer is sufficiently designed to release the second amount of the antiemetic drug over a period of at least 1 hour, wherein the solid oral dosage form is sufficiently designed to release the first amount of the first antiemetic drug and the second amount of the second antiemetic drug over a minimum period of 16 hours.
Reza Fathi, Gilead Raday
Filed: 30 Jun 20
Utility
Method for treating crohn's disease using triple antimicrobial all-in-one formulation
7 Sep 20
Oral administration of a solid dosage form of the present invention comprising an effective amount of rifabutin, an effective amount of clarithromycin, an effective amount of clofazimine, and an effective amount of an absorption enhancer, is used to treat a subject suffering from, or susceptible to, Mycobacterium avium subspecies paratuberculosis infection.
Thomas Julius Borody, Patrick Gosselin
Filed: 27 Aug 19
Utility
Methods for Treating Diarrhea Predominant Irritable Bowel Syndrome
12 Aug 20
A method of treating a patient comprises orally administering a solid oral dosage form comprising a core comprising a non-ionic polymer matrix, a first amount of ondansetron dispersed within the matrix, and a salt dispersed within the matrix, wherein the first amount of ondansetron ranges from about 9 mg to about 28 mg; a first seal coat surrounding the core, wherein the first seal coat is comprised of a non-ionic polymer matrix; and an immediate release drug layer surrounding the first seal coat and comprising a non-ionic polymer and a second amount of ondansetron dispersed therein, wherein the second amount of ondansetron ranges from about 3 mg to about 8 mg, wherein release of ondansetron from the solid oral dosage form provides exposure to ondansetron for a minimum period of 16 hours so as to result in a reduction in frequency of vomiting, nausea, diarrhea, or a combination thereof.
Reza Fathi, Gilead Raday, Guy Goldberg
Filed: 28 Apr 20
Utility
Formulations and Methods of Manufacturing Formulations for Use In Colonic Evacuation
15 Jul 20
Formulations and methods of manufacturing formulations for use in colonic evacuation are disclosed herein, in an embodiment, a solid dosage formulation includes an intra-granular fraction intermingled with an extra-granular fraction, wherein the intra-granular fraction includes granules comprising at least one osmotic evacuant agent, at least one antacid, and a first pharmaceutically acceptable excipient component, and wherein the extra-granular fraction includes one or more organic acids, a non-metallic lubricating element, and a second pharmaceutically acceptable excipient component.
Reza Fathi, Patrick Laughlin Mclean
Filed: 24 Oct 19
Utility
Fixed-dose Pharmaceutical Composition Comprising Rifabutin, Clarithromycin, and Clofazimine
1 Jul 20
Oral administration of a solid dosage form of the present invention comprising an effective amount of rifabutin, an effective amount of clarithromycin, an effective amount of clofazimine, and an effective amount of an absorption enhancer, is used to treat a subject suffering from, or susceptible to, Mycobacterium avium subspecies paratuberculosis infection.
Thomas Julius Borody, Patrick Gosselin
Filed: 11 Mar 20
Utility
Compositions, methods and kits for treating diarrhea-predominant irritable bowel syndrome
1 Jun 20
A method of treating a patient comprises orally administering a solid oral dosage form comprising a core comprising a non-ionic polymer matrix, a first amount of ondansetron dispersed within the matrix, and a salt dispersed within the matrix, wherein the first amount of ondansetron ranges from about 9 mg to about 28 mg; a first seal coat surrounding the core, wherein the first seal coat is comprised of a non-ionic polymer matrix; and an immediate release drug layer surrounding the first seal coat and comprising a non-ionic polymer and a second amount of ondansetron dispersed therein, wherein the second amount of ondansetron ranges from about 3 mg to about 8 mg, wherein release of ondansetron from the solid oral dosage form provides exposure to ondansetron for a minimum period of 16 hours so as to result in a reduction in frequency of vomiting, nausea, diarrhea, or a combination thereof.
Reza Fathi, Gilead Raday, Guy Goldberg
Filed: 25 May 17
Utility
Compositions for Treating Ebola Virus Infection
20 May 20
Pharmaceutical compositions showing the ability to inhibit or suppress replication of a filovirus in an individual are disclosed.
Reza Fathi, Dror Ben-Asher, Guy Goldberg
Filed: 23 Jan 20
Design
Blister package
11 May 20
Reza Fathi, Joanne Speed, Craig Miller, Ira Kalfus
Filed: 31 Oct 18
Utility
Method for Treating Cancer with Combination Therapy
15 Apr 20
Provided are methods for treating cancer in a patient by administering at least one antibiotic selected from the group consisting of clofazimine, rifabutin and clarithromycin, in combination with an aryladamantane compound.
Reza Fathi, Dror Ben-Asher, Danielle Abramson
Filed: 16 Sep 19
Utility
Method for Treating Crohn's Disease Using Triple Antimicrobial All-in-one Formulation
29 Jan 20
Oral administration of a solid dosage form of the present invention comprising an effective amount of rifabutin, an effective amount of clarithromycin, an effective amount of clofazimine, and an effective amount of an absorption enhancer, is used to treat a subject suffering from, or susceptible to, Mycobacterium avium subspecies paratuberculosis infection.
Thomas Julius Borody, Patrick Gosselin
Filed: 27 Aug 19
Utility
Therapy for inhibition of single-stranded RNA virus replication
27 Jan 20
Pharmaceutical compositions showing the ability to inhibit or suppress replication of a filovirus in an individual are disclosed.
Reza Fathi, Dror Ben-Asher, Guy Goldberg
Filed: 1 May 18
Utility
Formulations and methods of manufacturing formulations for use in colonic evacuation
2 Dec 19
Formulations and methods of manufacturing formulations for use in colonic evacuation are disclosed herein, in an embodiment, a solid dosage formulation includes an intra-granular fraction intermingled with an extra-granular fraction, wherein the intra-granular fraction includes granules comprising at least one osmotic evacuant agent, at least one antacid, and a first pharmaceutically acceptable excipient component, and wherein the extra-granular fraction includes one or more organic acids, a non-metallic lubricating element, and a second pharmaceutically acceptable excipient component.
Reza Fathi, Patrick Laughlin Mclean
Filed: 12 Nov 18
Utility
Rifabutin-based Compositions and Methods for Treating Helicobacter Pylori Infection
6 Nov 19
Single oral solid dosage form comprising an immediate release first dosage composition having at least two antibiotic agents and a delayed release second dosage composition having a proton pump inhibitor are provided herein.
Reza Fathi, Gilead Raday, Guy Goldberg, Patrick Gosselin
Filed: 17 Jul 19
Utility
Combination therapies for treating cancer
4 Nov 19
Provided are methods for treating cancer in a patient by administering at least one antibiotic selected from the group consisting of clofazimine, rifabutin and clarithromycin, in combination with an aryladamantane compound.
Reza Fathi, Dror Ben-Asher, Danielle Abramson
Filed: 6 Nov 17
Utility
Methods of treating a bacterial infection using a fixed-dose pharmaceutical composition comprising three antibiotics
7 Oct 19
Oral administration of a solid dosage form of the present invention comprising an effective amount of rifabutin, an effective amount of clarithromycin, an effective amount of clofazimine, and an effective amount of an absorption enhancer, is used to treat a subject suffering from, or susceptible to, Mycobacterium avium subspecies paratuberculosis infection.
Thomas Julius Borody, Patrick Gosselin
Filed: 28 Oct 18